Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

This publication has 42 references indexed in Scilit:

• Sofosbuvir as treatment against dengue?
  Chemical Biology & Drug Design, 2017
• Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
  Proceedings of the Japan Academy, Series B, 2017
• The FDA-approved drug sofosbuvir inhibits Zika virus infection
  Antiviral Research, 2017
• An introduction to multiplicity issues in clinical trials: the what, why, when and how
  International Journal of Epidemiology, 2016
• Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease
  AIDS, 2016
• Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza
  BMC Infectious Diseases, 2015
• Nitazoxanide: A first-in-class broad-spectrum antiviral agent
  Antiviral Research, 2014
• Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials
  Malaria Journal, 2013
• Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa
  Malaria Journal, 2012
• Effect of Oseltamivir, Zanamivir or Oseltamivir– Zanamivir Combination Treatments on Transmission of Influenza in Households
  Antiviral Therapy, 2012